SCHEMBL5451938

SCHEMBL5451938

COc1ccc(C=CC=O)c(C)c1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 1/20 0.44
CYP1A1 P04798 7/20 0.40
CYP1B1 Q16678 7/20 0.40
CYP1A2 P05177 6/20 0.40
CDK4 P11802 3/20 0.40
CCND1 P24385 3/20 0.40
NFE2L2 Q16236 2/20 0.40
TRPA1 O75762 1/20 0.39
MTNR1A P48039 1/20 0.39
ABCG2 Q9UNQ0 1/20 0.38
ALDH1A1 P00352 3/20 0.38
CCNB2 O95067 1/20 0.37
CDK1 P06493 1/20 0.37
CCNB1 P14635 1/20 0.37
CCNB3 Q8WWL7 1/20 0.37
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
TSHR P16473 1/20 0.36
TFEB P19484 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formaldehyde SCHEMBL5462063 0.96 XDH (0.41) XDHCYP1A1CYP1B1CYP1A2CDK4
SCHEMBL18570324 0.85 CDK4 (0.50) XDHCYP1A1CYP1B1CYP1A2CDK4
SCHEMBL746936 0.81 ABCG2 (0.57) XDHCYP1A1CYP1B1CYP1A2NFE2L2
SCHEMBL7198703 0.81 ABCG2 (0.57) XDHCYP1A1CYP1B1CYP1A2NFE2L2
SCHEMBL29953692 0.80 ALDH1A1 (0.52) ALDH1A1TSHR
SCHEMBL851964 0.80 ALDH1A1 (0.52) ALDH1A1TSHR
SCHEMBL23957930 0.79 CYP3A4 (0.50) CYP1A1CYP1B1CYP1A2NFE2L2ABCG2
SCHEMBL10917406 0.78 ALDH1A1 (0.46) NFE2L2ABCG2ALDH1A1MEN1MAPT
SCHEMBL10917402 0.78 ALDH1A1 (0.46) NFE2L2ABCG2ALDH1A1MEN1MAPT
SCHEMBL13807149 0.78 ACHE (0.50) XDHCYP1A1CYP1B1CYP1A2NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249616-A1 Substituted 1-Benzyl-4-Substituted Piperazine Analogues NEUROGEN CORPORATION (US) 2007-10-25 US disclosed
US-7253168-B2 Substituted 1-benzyl-4-substituted piperazine analogues NEUROGEN CORPORATION (US) 2007-08-07 US disclosed
US-20060142301-A1 Substituted 1-benzyl-4-substituted piperazine analogues NEUROGEN CORPORATION 2006-06-29 US disclosed
US-20060009456-A1 Aryl-substituted piperazine derivatives NEUROGEN CORPORATION 2006-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249616-A1 Substituted 1-Benzyl-4-Substituted Piperazine Analogues MCHR1, MCHR2, PRLHR XDH 2773/4885CYP1A1 356/4885CYP1B1 198/4885
US-20060009456-A1 Aryl-substituted piperazine derivatives MCHR1, MCHR2, PRLHR XDH 2168/4885CYP1A1 461/4885CYP1B1 486/4885
US-20060142301-A1 Substituted 1-benzyl-4-substituted piperazine analogues MCHR1, MCHR2, PRLHR XDH 2773/4885CYP1A1 356/4885CYP1B1 198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.